141 related articles for article (PubMed ID: 37981895)
1. Germline bi-allelic
Arfeuille C; Vial Y; Cadenet M; Caye-Eude A; Fenneteau O; Neven Q; Bonnard AA; Pizzi S; Carpentieri G; Capri Y; Girardi K; Pedace L; Macchiaiolo M; Boudhar K; Khaled MB; Chahla WA; Lutun A; Fahd M; Drunat S; Flex E; Dalle JH; Strullu M; Locatelli F; Tartaglia M; Cavé H
Haematologica; 2023 Nov; ():. PubMed ID: 37981895
[TBL] [Abstract][Full Text] [Related]
2. LNK/
Wintering A; Hecht A; Meyer J; Wong EB; Hübner J; Abelson S; Feldman K; Kennedy VE; Peretz CAC; French DL; Maguire JA; Jobaliya C; Vasquez MR; Desai S; Dulman R; Nemecek E; Haines H; Hammad M; El Haddad A; Kogan SC; Abdullaev Z; Chehab FF; Tasian SK; Smith CC; Loh ML; Stieglitz E
Haematologica; 2023 Dec; ():. PubMed ID: 38152053
[TBL] [Abstract][Full Text] [Related]
3. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
[TBL] [Abstract][Full Text] [Related]
4. Juvenile myelomonocytic leukemia-A comprehensive review and recent advances in management.
Gupta AK; Meena JP; Chopra A; Tanwar P; Seth R
Am J Blood Res; 2021; 11(1):1-21. PubMed ID: 33796386
[TBL] [Abstract][Full Text] [Related]
5. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
[TBL] [Abstract][Full Text] [Related]
6. Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia.
Morales CE; Stieglitz E; Kogan SC; Loh ML; Braun BS
Blood Adv; 2021 Sep; 5(18):3587-3591. PubMed ID: 34464969
[TBL] [Abstract][Full Text] [Related]
7. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
Lasho T; Patnaik MM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
[TBL] [Abstract][Full Text] [Related]
8. The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
Maslah N; Cassinat B; Verger E; Kiladjian JJ; Velazquez L
Leukemia; 2017 Aug; 31(8):1661-1670. PubMed ID: 28484264
[TBL] [Abstract][Full Text] [Related]
9. JMML genomics and decisions.
Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325
[TBL] [Abstract][Full Text] [Related]
10. Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia.
Fiñana C; Gómez-Molina N; Alonso-Moreno S; Belver L
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267643
[TBL] [Abstract][Full Text] [Related]
11. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
[TBL] [Abstract][Full Text] [Related]
12. [Juvenile myelomonocytic leukemias].
Lachenaud J; Strullu M; Baruchel A; Cavé H
Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
[TBL] [Abstract][Full Text] [Related]
13. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Niemeyer CM; Flotho C
Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
[TBL] [Abstract][Full Text] [Related]
14. Distinctive phenotypes in two children with novel germline
Bagla S; Regling KA; Wakeling EN; Gadgeel M; Buck S; Zaidi AU; Flore LA; Chicka M; Schiffer CA; Chitlur MB; Ravindranath Y
Pediatr Hematol Oncol; 2021 Feb; 38(1):65-79. PubMed ID: 32990483
[No Abstract] [Full Text] [Related]
15. The Missing LNK: Evolution from Cytosis to Chronic Myelomonocytic Leukemia in a Patient with Multiple Sclerosis and Germline SH2B3 Mutation.
Gundabolu K; Dave BJ; Alvares CJ; Cannatella JJ; Bhatt VR; Maness LJ; Al-Kadhimi ZS; Zabad RK; Cushman-Vokoun AM
Case Rep Genet; 2022; 2022():6977041. PubMed ID: 35281324
[TBL] [Abstract][Full Text] [Related]
16. Juvenile myelomonocytic leukaemia and Noonan syndrome.
Strullu M; Caye A; Lachenaud J; Cassinat B; Gazal S; Fenneteau O; Pouvreau N; Pereira S; Baumann C; Contet A; Sirvent N; Méchinaud F; Guellec I; Adjaoud D; Paillard C; Alberti C; Zenker M; Chomienne C; Bertrand Y; Baruchel A; Verloes A; Cavé H
J Med Genet; 2014 Oct; 51(10):689-97. PubMed ID: 25097206
[TBL] [Abstract][Full Text] [Related]
17. Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia.
Gratias EJ; Liu YL; Meleth S; Castleberry RP; Emanuel PD
Pediatr Blood Cancer; 2005 Feb; 44(2):142-6. PubMed ID: 15390271
[TBL] [Abstract][Full Text] [Related]
18. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
Sakashita K
Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
[TBL] [Abstract][Full Text] [Related]
19. Mutational landscape of Juvenile Myelomonocytic Leukemia (JMML)-A real-world context.
Nathany S; Chatterjee G; Ghai S; Moulik NR; Shetty D; Subramanian PG; Tembhare P; Gujral S; Dhamne C; Banavali S; Narula G; Patkar N
Int J Lab Hematol; 2021 Dec; 43(6):1531-1538. PubMed ID: 34387930
[TBL] [Abstract][Full Text] [Related]
20. Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity.
Wang W; Li X; Qin X; Miao Y; Zhang Y; Li S; Yao R; Yang Y; Yu L; Zhu H; Song L; Mao S; Wang X; Chen J; Feng H; Li Y
Br J Haematol; 2023 Jul; 202(2):328-343. PubMed ID: 37144690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
